View Older Stories View More Recent Stories
-
Zimmer Biomet Holdings (ZBH) Tops Q1 EPS by 22c
-
Leerink Partners Starts Zimmer Biomet (ZBH) at Market Perform
-
Zimmer Biomet appoints Jonathan M. Vigdorchik as chief science officer
-
Argus on Zimmer Biomet (ZBH): 'this as an attractive valuation'
-
BTIG Downgrades Zimmer Biomet (ZBH) to Neutral
-
William Blair Starts Zimmer Biomet (ZBH) at Market Perform
-
Zimmer Biomet Holdings (ZBH) Tops Q4 EPS by 2c, Beats on Revenue; Offers FY26 EPS Guidance
-
TD Cowen New Analyst on Zimmer Biomet (ZBH) at Buy: 'The Decks Are Clearing'
-
Bernstein Highlights Top U.S. Medtech 2026 Picks: 'Sector Poised For a Rebound'
-
Goldman Sachs Downgrades Zimmer Biomet (ZBH) to Sell
-
Raymond James Downgrades Zimmer Biomet (ZBH) to Market Perform
-
Zimmer Biomet Holdings (ZBH) Declares $0.24 Quarterly Dividend; 1.1% Yield
-
Zimmer Biomet partners with OneStep for mobility tracking platform
-
Baird Downgrades Zimmer Biomet (ZBH) to Neutral
-
This is the best orthopedics stock to own in 2026, Wolfe says
-
Piper Sandler Shares Medical Technology and Devices Stock Thoughts Post Ortho KOL Call
-
Zimmer Biomet gets FDA clearance for enhanced ROSA knee surgery robot
-
Zimmer Biomet (ZBH) PT Lowered at Bernstein Amid Organic Growth Miss
-
Zimmer Biomet (ZBH) PT Lowered to $120 at Citizens on 'three Negative Surprises'
-
JPMorgan Downgrades Zimmer Biomet (ZBH) to Neutral
-
Zimmer Biomet (ZBH) PT Lowered to $101 at RBC Capital, 'Q3 Surprise Miss Puts Operational Controls in Focus'
-
Zimmer Biomet Holdings (ZBH) Tops Q3 EPS by 3c; maintains guidance
-
Zimmer Biomet receives FDA breakthrough designation for iodine hip system
-
Zimmer Biomet launches two foot and ankle trauma solutions
-
Zimmer Biomet receives Japan approval for iodine-treated hip implants
-
Zimmer Biomet (ZBH) PT Raised to $118 at Stifel After Doc Check
-
Rothschild Redburn Starts Zimmer Biomet (ZBH) at Buy
-
Zimmer Biomet names two new chief medical advisors
-
Citizens JMP Reiterates Market Outperform Rating on Zimmer Biomet (ZBH)
-
Zimmer Biomet (ZBH) PT Raised to $105 at Bernstein SocGen Group
-
Zimmer Biomet Holdings (ZBH) Tops Q2 EPS by 9c, provides guidance
-
Roth/MKM Upgrades Zimmer Biomet (ZBH) to Buy
-
BTIG Reiterates Buy Rating on Zimmer Biomet (ZBH)
-
Citi on Zimmer Biomet (ZBH): 'This is another step in its transformation path'
-
Zimmer Biomet to acquire Monogram Technologies for $177 million
-
Treace Files Patent Infringement Suit Against Zimmer Biomet Holdings (ZBH)
-
Zimmer Biomet Holdings (ZBH) Declares $0.24 Quarterly Dividend; 1% Yield
-
Zimmer Biomet Holdings (ZBH) Appoints Kevin Thornal as Group President, Global Businesses and the Americas
-
Zimmer Biomet (ZBH) PT Lowered to $100 at Bernstein SocGen Group
-
UBS Reiterates Sell Rating on Zimmer Biomet (ZBH)
-
Zimmer Biomet (ZBH) PT Lowered to $104 at TD Cowen Amid Tariff Uncertainties
-
Zimmer Biomet (ZBH) PT Lowered to $95 at Morgan Stanley
-
Zimmer Biomet (ZBH) PT Lowered to $115 at Stifel
-
Zimmer Biomet (ZBH) PT Lowered to $104 at Raymond James
-
Zimmer Biomet (ZBH) PT Lowered to $102 at Evercore ISI
-
Zimmer Biomet (ZBH) PT Lowered to $117 at BTIG
-
Zimmer Biomet (ZBH) PT Lowered to $104 at Citi
-
Zimmer Biomet Holdings (ZBH) Tops Q1 EPS by 4c ; Offers Guidance
-
Zimmer Biomet Holdings (ZBH) call put ratio 5.6 calls to 1 put into quarter results
-
RBC Capital Assesses U.S. Tariff Impact Across Industries

